Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-1150 in Elevated LDL-C
NCT07428473Phase 1Recruiting
- Sponsor
- Monash University
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of STX1150 in hypercholesterolemia, sponsored by Monash University. Primary endpoints: Incidence and Severity of Treatment-Emergent Adverse Events at 52 weeks, Incidence and Severity of Serious Adverse Events at 52 weeks and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
STX1150
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07428473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428473.